Abstract:Abstract Introduction: Locally advanced esophageal adenocarcinoma (EAC) remains difficult to treat, and resistance is common. The ecological and evolutionary dynamics responsible for treatment failure are incompletely understood. Aim & Methods: We performed a multi-omic study with a multi-timepoint strategy to examine neoadjuvant treatment response at clonal resolution and in the surrounding tumor microenvironment. EAC samples from chemotherapy responding (REs) and chemotherapy non-responding (NRs) patients with locally advanced EAC were collected at three time points (prior, during, and after neoadjuvant therapy) within the multicenter MEMORI trial. Whole exome sequencing (mean depth 300x) was performed on 47 samples from 17 REs and on 24 samples from 10 NRs. Matched RNA sequencing was performed on 53 samples from 17 REs and on 26 samples from 10 NRs. To characterize immune response we performed imaging mass cytometry (IMC) with a 18-marker panel on 26 samples from 9 REs and 16 samples from 6 NRs and T-cell receptor sequencing in 18 RE-samples and 9 NR-samples. Results: We observed profound changes in mutation signatures over time, characterized by C>A transitions after exposure to neoadjuvant chemotherapy (FOLFOX), which is consistent with earlier observed oxaliplatin induced mutational signatures. Phylogenetic analysis showed no major changes in the clonal make-up during treatment, suggesting phenotypic plasticity rather than clonal evolution caused treatment resistance. EAC samples displayed widespread copy number alterations (CNAs), as previously described. CNAs arising during treatment were significantly more likely to be small, focal alterations rather than large alterations. At the transcriptome level neoadjuvant treatment led to significant changes with significant upregulation of immune and stromal pathways and oncogenic pathways such as KRAS, Hedgehog and WNT. The presence of immune escape mechanisms (defined as LOH or mutations in HLA, B2M mutations or PDL-1 overexpression) and a lack of clonal T-cell expansions were linked to poor clinical treatment response. Moreover, IMC analyses showed a less activated T-cell phenotype in NRs than in REs throughout treatment. Conclusion: Using a multi-timepoint approach, we integrated genetic analyses with transcriptomic analyses and analyses of the tumor immune microenvironment for a holistic understanding of treatment resistance. This study identifies profound transcriptional changes during treatment with limited evidence that clonal replacement is the cause, suggesting phenotypic plasticity as a mechanism for therapy resistance. The presence of immune escape, a less activated T-cell phenotype and a lack of clonal T-cell expansions in patients with poor clinical treatment response has high pharmacological relevance and could be exploited via combined immune-chemotherapy treatments. Citation Format: Melissa Barroux, Jacob Househam, Eszter Lakatos, Tahel Ronel, Ann-Marie Baker, Henrike Salié, Max Mossner, Kane Smith, Chris Kimberley, Salpie Nowinski, Alison Berner, Vinaya Gunasri, Marnix Jansen, Giulio Caravagna, Julia Slotta-Huspenina, Wilko Weichert, Markus Alberstmeier, Benny Chain, Helmut Friess, Bertram Bengsch, Roland M. Schmid, Jens T. Siveke, Michael Quante, Trevor A. Graham. Tumor evolution and immune microenvironment dynamics define response to neoadjuvant treatment of esophageal adenocarcinoma. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4539.

Correction for Ebbing et al., Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma

Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma

Correction: Antón-García et al. TGFβ1-Induced EMT in the MCF10A Mammary Epithelial Cell Line Model Is Executed Independently of SNAIL1 and ZEB1 but Relies on JUNB-Coordinated Transcriptional Regulation. Cancers 2023, 15, 588

Abstract 4539: Tumor evolution and immune microenvironment dynamics define response to neoadjuvant treatment of esophageal adenocarcinoma

Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Correction: The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report

Erratum: ITGA2 Overexpression Promotes Esophageal Squamous Cell Carcinoma Aggression via FAK/AKT Signaling Pathway [Corrigendum]

Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer

Correction: Siu et al. Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades. Cancers 2019, 11, 813

Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER + HER2 − metastatic breast cancer: a phase 1 trial

Abstract 1745: Targeting therapeutic resistance of esophageal adenocarcinoma through modulating the epithelial-to-mesenchymal transition via NFκB-mediated signaling

Correction: Endoscopic Removal of an Extraluminal Gastrointestinal Stromal Tumor Recurrence Located on the Surgical Stapler Line at Gastroesophageal Junction

Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998

[Corrigendum] Macrophage‑secreted IL‑8 induces epithelial‑mesen-chymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway.

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Tumor-Secreted Extracellular Vesicles Counteract Therapy Response by Triggering Inflammatory Mesenchymal Stem Cell Development

Erratum: CD151 promotes Colorectal Cancer progression by a crosstalk involving CEACAM6, LGR5 and Wnt signaling via TGFβ1: Erratum.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Correction to: The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression